- Perry RD, Fetherston JD. Yersinia pestis—etiologic agent of plague. Clin Microbiol Rev1997; 10: 35–66.
- Gage KL, Kosoy MY. Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol2005; 50: 505–528.
- Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA2000; 283: 2281–2290.
- Feodorova VA, Corbel MJ. Prospects for new plague vaccines. Expert Rev Vaccines2009; 8: 1721–1738.
- Galimand M, Guiyoule A, Gerbaud G et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Eng J Med1997; 337: 677–680.
- Guiyoule A, Gerbaud G, Buchrieser C et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis2001; 7: 43–48.
- Kiefer D, Dalantai G, Damdindorj T et al. Phenotypical characterization of Mongolian Yersinia pestis strains. Vector Borne Zoonotic Dis2012; 12: 183–188.
- Bos KI, Schuenemann VJ, Golding GB et al. A draft genome of Yersinia pestis from victims of the Black Death. Nature2011; 478: 506–510.
- Morelli G, Song Y, Mazzoni CJ et al. Yersinia pestis genome sequencing identifies patterns of global phylogenetic diversity. Nat Genet2010; 42: 1140–1143.
- Girard G. [Immunity in plague infection. Results of 30 years of work with the Pasteurella pestis EV strain (Girard and Robic).] Biol Med (Paris)1963; 52: 631–731. French.
- Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine1995; 13: 1551–1556.
- Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull WHO1970; 42: 653–666.
- Meyer KF, Smith G, Foster L, Brookman M, Sung M. Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs. J Infect Dis1974; 129 (Suppl): S85–S112.
- Korobkova EI. Live antiplague vaccine. Moscow: Medgiz, 1956.
- Fetherston JD, Schuetze P, Perry RD. Loss of the pigmentation phenotype in Yersinia pestis is due to the spontaneous deletion of 102 kb of chromosomal DNA which is flanked by a repetitive element. Mol Microbiol1992; 6: 2693–2704.
- Fetherston JD, Perry RD. The pigmentation locus of Yersinia pestis KIM6+ is flanked by an insertion sequence and includes the structural genes for pesticin sensitivity and HMWP2. Mol Microbiol1994; 13: 697–708.
- Feodorova VA, Motin VL. Plague vaccines. In: Feodorova VA, Motin VL (eds.)Vaccines against bacterial biothreat pathogens. Kerala: Research Signpost 2011: 176–233.
- Andrews GP, Heath DG, Anderson GW Jr , Welkos SL, Friedlander AM. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun1996; 64: 2180–2187.
- Motin VL, Nakajima R, Smirvov GB, Brubaker RR. Passive immunity to yersiniae mediated by anti-recombinant V antigen and Protein A–V antigen fusion peptide. Infect Immun1994; 62: 4192–4201.
- Nakajima R, Motin VL, Brubaker RR. Suppression of cytokines in mice by Protein A–V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun1995; 63: 3021–3029.
- Motin VL, Nedialkov YA, Brubaker RR. V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague. Infect Immun1996; 64: 4313–4318.
- Williamson ED, Eley SM, Griffin KF et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol1995; 12: 223–230.
- Quenee LE, Schneewind O. Plague vaccines and the molecular basis of immunity against Yersinia pestis. Hum Vaccin2009; 5: 817–823.
- Smiley ST. Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines2008; 7: 209–221.
- Titball RW, Williamson ED. Vaccination against bubonic and pneumonic plague. Vaccine2001; 19: 4175–4184.
- Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther2004; 4: 965–973.
- Williamson ED, Titball RW. Vaccines against dangerous pathogens. Br Med Bull2002; 62: 163–173.
- Williamson ED, Duchars MG, Kohberger R. Predictive models and correlates of protection for testing biodefence vaccines. Expert Rev Vaccines2010; 9: 527–537.
- Brubaker RR. Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun2003; 71: 3673–3681.
- DeBord KL, Anderson DM, Marketon MM et al. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infect Immun2006; 74: 4910–4914.
- Nedialkov YA, Motin VL, Brubaker RR. Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun1997; 65: 1196–1203.
- Anisimov AP, Dentovskaya SV, Panfertsev EA et al. Amino acid and structural variability of Yersinia pestis LcrV protein. Infect Genet Evol2010; 10: 137–145.
- Motin VL, Pokrovskaya MS, Telepnev MV et al. The difference in the lcrV sequences between Yersinia pestis and Yersinia pseudotuberculosis and its application for characterization of Y. pseudotuberculosis strains. Microb Pathog1992; 12: 165–175.
- Cornelius CA, Quenee LE, Overheim KA et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun2008; 76: 5588–5597.
- Fellows P, Adamovicz J, Hartings J et al. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine2010; 28: 7748–7756.
- Welkos S, Norris S, Adamovicz J. Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection. Clin Vaccine Immunol2008; 15: 1134–1137.
- Williamson ED, Packer PJ, Waters EL et al. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine2011; 29: 4771–4777.
- Mizel SB, Graff AH, Sriranganathan N et al. Flagellin–F1–V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol2009; 16: 21–28.
- Qiu Y, Liu Y, Qi Z et al. Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta. Scand J Immunol2010; 72: 425–433.
- Stacy S, Pasquali A, Sexton VL, Cantwell AM, Kraig E, Dube PH. An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen. J Immunol2008; 181: 109–115.
- Williamson ED, Flick-Smith HC, Lebutt C et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun2005; 73: 3598–3608.
- Bashaw J, Norris S, Weeks S, Trevino S, Adamovicz JJ, Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vaccine Immunol2007; 14: 605–616.
- Lin JS, Park S, Adamovicz JJ et al. TNFalpha and IFNgamma contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine2010; 29: 357–362.
- Weeks S, Hill J, Friedlander A, Welkos S. Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis. Microb Pathog2002; 32: 227–237.
- Wang S, Heilman D, Liu F et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine2004; 22: 3348–3357.
- Wang S, Joshi S, Mboudjeka I et al. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine2008; 26: 1664–1674.
- Wang Z, Zhou L, Qi Z et al. Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice. Clin Vaccine Immunol2010; 17: 199–201.
- Torres-Escobar A, Juarez-Rodriguez MD, Gunn BM, Branger CG, Tinge SA, Curtiss R 3rd. Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice. Infect Immun2010; 78: 2529–2543.
- Sun W, Roland KL, Curtiss R 3rd. Developing live vaccines against Yersinia pestis. J Infect Dev Ctries2011; 5: 614–627.
- Daniel C, Sebbane F, Poiret S et al. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV. Vaccine2009; 27: 1141–1144.
- Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis2006; 194: 1249–1257.
- Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE2008; 3: e3548.
- Chattopadhyay A, Park S, Delmas G et al. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine2008; 26: 6329–6337.
- Rocke TE, Iams KP, Dawe S et al. Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis). Vaccine2009; 28: 338–344.
- Brewoo JN, Powell TD, Stinchcomb DT, Osorio JE. Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice. Vaccine2010; 28: 5891–5899.
- Saltykova RA, Faibich MM. [Experience from a 30-year study of the stability of the properties of the plague vaccine strain EV in the USSR.] Zh Mikrobiol Epidemiol Immunobiol1975; 6: 3–8. Russian.
- Feodorova VA, Pan’kina LN, Savostina EP et al. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine2007; 25: 7620–7628.
- Feodorova VA, Pan’kina LN, Savostina EP et al. Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens. Vaccine2009; 27: 2240–2250.
- Montminy SW, Khan N, McGrath S et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol2006; 7: 1066–1073.
- Sha J, Agar SL, Baze WB et al. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun2008; 76: 1390–1409.
- Tidhar A, Flashner Y, Cohen S et al. The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS ONE2009; 4: e7023.
- Alvarez ML, Cardineau GA. Prevention of bubonic and pneumonic plague using plant-derived vaccines. Biotechnol Adv2010; 28: 184–196.
- Lin JS, Kummer LW, Szaba FM, Smiley ST. IL-17 contributes to cell-mediated defense against pulmonary yersinia pestis infection. J Immunol2011; 186: 1675–1684.
- Smiley ST. Cell-mediated defense against Yersinia pestis infection. Adv Exp Med Biol2007; 603: 376–386.
- Smiley ST. Immune defense against pneumonic plague. Immunol Rev2008; 225: 256–271.
- Li B, Zhou L, Guo J et al. High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay. Infect Immun2009; 77: 4356–4561.
- Wang S, Goguen JD, Li F, Lu S. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine2011; 29: 6802–6809.
- Nakajima R, Brubaker RR. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun1993; 61: 23–31.
- Knirel YA, Dentovskaya SV, Senchenkova SN, Shaikhutdinova RZ, Kocharova NA, Anisimov AP. Structural features and structural variability of the lipopolysaccharide of Yersinia pestis, the cause of plague. J Endotoxin Res2006; 12: 3–9.
- Telepnev MV, Klimpel GR, Haithcoat J, Knirel YA, Anisimov AP, Motin VL. Tetraacylated lipopolysaccharide of Yersinia pestis can inhibit multiple Toll-like receptor-mediated signaling pathways in human dendritic cells. J Infect Dis2009; 200: 1694–1702.
- Price PA, Jin J, Goldman WE. Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation. Proc Natl Acad Sci USA2012; 109: 3083–3088.
- Lu S. Two is better than one. Lancet Infect Dis2011; 11: 889–891.
Emerging Microbes & Infections
Volume 1, 2012 - Issue 1